Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4299924 | 1.00 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL577429 | 1.00 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL8199316 | 1.00 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL22003 | 1.00 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL7052601 | 1.00 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL5033222 | 1.00 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Piperazine SCHEMBL734764 | 1.00 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL3999265 | 1.00 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL576335 | 1.00 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Piperazine SCHEMBL8010246 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240200078-A1 | MICRORNA-DEPENDENT MRNA SWITCHES FOR TISSUE-SPECIFIC MRNA-BASED THERAPIES | CORNELL UNIVERSITY | 2024-06-20 | — | — | US | disclosed |
| WO-2024112568-A1 | ANTISENSE OLIGOMER (ASO) AS AN INHIBITOR OF LIVER FIBROSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-05-30 | — | — | WO | disclosed |
| EP-4352228-A2 | USE OF MICRORNA MIMICS TO INHIBIT OR TREAT LIVER DISEASE | Cornell University (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117794585-A | Radioimmunoconjugates and checkpoint inhibitor combination therapies | 融合制药公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230293434-A1 | COMPOSITIONS COMPRISING miR-690 AND METHODS THEREFOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-09-21 | — | — | US | disclosed |
| WO-2023130022-A2 | CYSTATIN RNA COMPOSITIONS FOR TISSUE ENGINEERING | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230040042-A1 | MANUFACTURING OF PROTECTED DO3A | BRACCO IMAGING S.P.A. (IT) | 2023-02-09 | — | — | US | disclosed |
| CN-114845998-A | Preparation of protected DO3A | 伯拉考成像股份公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-113727737-A | Tumor extracellular matrix oncoprotein specific peptide PET/SPECT probe | 卡斯西部储备大学 | 2021-11-30 | — | — | CN | disclosed |
| WO-2021116165-A1 | MANUFACTURING OF PROTECTED DO3A | BRACCO IMAGING SPA (IT) | 2021-06-17 | — | — | WO | disclosed |
| WO-2011117350-A1 | ELECTROCHEMICAL TEXTILE-WASHING METHOD | BASF SE (DE) | 2011-09-29 | — | — | WO | disclosed |
| US-20090143529-A1 | Peptide purification by means of hard metal ion affinity chromatography | HEARN MILTON THOMAS WILLIAM | 2009-06-04 | — | — | US | disclosed |
| US-5756065-A | DIAGNOSTIC CHELATES FOR ANTIBODIES AND RADIOACTIVE MATERIALS | THE DOW CHEMICAL COMPANY (US) | 1998-05-26 | — | — | US | disclosed |
| US-5739022-A | CLEAVAGE PHOSPHORUS, OXYGEN LINKAGE FO NUCLEIC ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1998-04-14 | — | — | US | disclosed |
| US-5652361-A | ANTITUMOR | THE DOW CHEMICAL COMPANY (US) | 1997-07-29 | — | — | US | disclosed |
| US-5435990-A | Chelate-antibody complexes, treatment and diagnosis of cancer, tetraazacyclododecane compounds | THE DOW CHEMICAL COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0353450-B1 | Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates | DOW CHEMICAL CO (US) | 1995-03-29 | — | — | EP | disclosed |
| EP-0420942-A1 | MACROCYCLIC BIFUNCTIONAL CHELANTS, COMPLEXES THEREOF AND THEIR ANTIBODY CONJUGATES | THE DOW CHEMICAL COMPANY (US) | 1991-04-10 | — | — | EP | disclosed |
| EP-0353450-A1 | Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates | THE DOW CHEMICAL COMPANY (US) | 1990-02-07 | — | — | EP | disclosed |
| WO-1989012631-A1 | MACROCYCLIC BIFUNCTIONAL CHELANTS, COMPLEXES THEREOF AND THEIR ANTIBODY CONJUGATES | THE DOW CHEMICAL COMPANY (US) | 1989-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143529-A1 | Peptide purification by means of hard metal ion affinity chromatography | MAX, PTMS, SLC7A1 | HIF1A 1822/4885MAPT 2874/4885PDE4A 4726/4885 |
| US-20230040042-A1 | MANUFACTURING OF PROTECTED DO3A | TET3, SF3A3, DCTN3 | HIF1A 1620/4885MAPT 3416/4885PDE4A 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.